Gold prices edge higher on raised Fed rate cut hopes
BRENTWOOD, TN—Ramkumar Mandalam, a director at Cryoport, Inc. (NASDAQ:CYRX), has sold a total of $75,348 worth of the company’s common stock, according to a recent SEC filing. The transactions occurred over three consecutive days, from June 11 to June 13, 2025. The sales come as Cryoport, currently valued at $334 million, trades near $6.67 per share, approximately 36% lower than a year ago. According to InvestingPro analysis, the stock appears slightly undervalued based on its Fair Value assessment.
On June 11, Mandalam sold 8,193 shares at a weighted average price of $7.0567 per share, with individual sale prices ranging from $7.00 to $7.05. The following day, June 12, he sold an additional 1,895 shares at a weighted average price of $7.0113, with prices ranging from $7.00 to $7.03. The final sale on June 13 involved 624 shares at a price of $6.8047 per share. InvestingPro data shows the company maintains strong liquidity with a current ratio of 5.56, though analysts anticipate sales decline this year.
Following these transactions, Mandalam now holds 66,377 shares of Cryoport stock. Get deeper insights into CYRX’s valuation, financial health scores, and more exclusive metrics with InvestingPro’s comprehensive research report, part of their coverage of over 1,400 US stocks.
In other recent news, Cryoport Inc . has completed the sale of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash. This strategic move is accompanied by a partnership aimed at enhancing supply chain services for the global life sciences and healthcare sectors. The transaction is expected to provide Cryoport with additional capital to focus on its Life Science Services platform, particularly in the regenerative medicine market. Meanwhile, Cryoport reported its first-quarter 2025 earnings, revealing an earnings per share of -$0.28, which was better than the forecasted -$0.31. However, the company fell short on revenue, generating $41 million against a forecast of $58.96 million, marking a significant revenue miss. Despite this, Cryoport’s life sciences services revenue rose by 17%, with commercial cell and gene therapies growing by 33%. The company has confirmed its full-year 2025 revenue guidance of $165-$172 million, representing a 7.5% growth at the midpoint. These developments reflect Cryoport’s strategic focus on expanding its global logistics capabilities and enhancing its core offerings in the life sciences sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.